Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient‐derived xenograft tumors. Issue 10 (20th August 2020)

• Record Type: Journal Article
• Authors: Dhar, Deepanshi; Raina, Komal; Kumar, Dileep; Wempe, Michael F.; Bagby, Stacey M.; Pitts, Todd M.; Orlicky, David J.; Agarwal, Chapla; Messersmith, Wells A.; Agarwal, Rajesh
• Is Part Of: Molecular carcinogenesis. Volume 59:Issue 10(2020)
• Page Start: 1227
• Page End: 1240
• Publication Date: 2020-08-20
• Subjects: bitter melon juice -- chemoresistance -- gemcitabine -- pancreatic cancer -- patient‐derived xenograft; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.23251
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract: Chemoresistance to gemcitabine (GEM)—a frontline chemotherapeutic, resulting from its dysfunctional uptake and metabolism in cancer cells, is a major contributing factor for failed therapy in pancreatic cancer (PanC) patients. Therefore, there is an urgent need for agents that could reverse GEM resistance and allow continued chemosensitivity to the drug. We employed natural nontoxic agent (with anti‐PanC potential) bitter melon juice (BMJ) and GEM to examine their combinatorial benefits against tumorigenesis of PanC patient‐derived xenograft (PDX)—pancreatic ductal adenocarcinomas explants PDX272 (wild‐type KRAS ), PDX271 (mutant KRAS and SMAD4 ), and PDX266 (mutant KRAS ). Anti‐PanC efficacy of single agents vs combination in the three tumor explants, both at the end of active dosing regimen and following a drug‐washout phase were compared. In animal studies, GEM alone treatment significantly inhibited PDX tumor growth, but effects were not sustained, as GEM‐treated tumors exhibited regrowth posttreatment termination. However, combination‐regimen displayed enhanced and sustained efficacy. Mechanistic assessments revealed that overcoming GEM resistance by coadministration with BMJ was possibly due to modulation of GEM transport/metabolism pathway molecules (ribonucleotide reductase regulatory subunit M1, human equilibrative nucleoside transporter 1, and deoxycytidine kinase). Study outcomes, highlighting significantly higher and sustained efficacy of GEM in combination with BMJ, make a compelling case for a clinical trial in PanC patients, wherein BMJ could be combined with GEM to target and overcome GEM resistance. In addition, given their specific effectiveness against KRAS ‐mutant tumors, this combination could be potentially beneficial to a broader PanC patient population.